TGen lands $15 million NCI grant
Summary:
The Translational Genomics Research Institute has received a five-year $15 million grant from the National Cancer Institute (NCI) to discover and develop new treatments for pancreatic cancer.
Full Story:
The Translational Genomics Research Institute has received a five-year $15 million grant from the National Cancer Institute (NCI) to discover and develop new treatments for pancreatic cancer.
The grant is the largest one TGen has received in its three-year history, and it establishes TGen as the leader of a multi-center program project grant that is the first of its kind that focuses exclusively on pancreatic cancer.
Dr. Daniel Von Hoff, director of TGen's translational drug development division will lead the study, which aims to produce one new cancer drug each year. The study includes three separate projects:
- Von Hoff and TGen's Dr. Haiyong Han will identify potential drugs that selectively kill tumor cells that contain certain deletions in their DNA
- Jeffrey Trent, director of TGen, and Spyro Mousses, director of TGen's cancer drug development laboratory, will use genetic manipulation to make pancreatic cancer tumor cells more sensitive to drugs
- A third project will be led by doctors at the University of Texas M.D. Anderson Cancer Center.
The Arizona Cancer Center will work with all three projects to develop drugs based on their findings.
For more information:
"TGen to lead $15 million cancer project," Arizona Republic, 10/19/2005